Patients with advanced RCC often face poor outcomes, especially if they have one or more risk factors. To learn more about a treatment option for intermediate- or poor-risk patients, Dr. John Russell welcomes Dr. Jeanny Aragon-Ching, who discusses clinical trial findings and their potential impact in this disease state.

This promotional, non-CME program is intended for U.S. physicians treating advanced RCC. Dr. Aragon-Ching is a paid consultant of Bristol-Myers Squibb.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous use.

Please see Important Safety Information for OPDIVO and YERVOY, including Boxed WARNING regarding immune-mediate adverse reactions for YERVOY, below.

WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS

YERVOY can result in severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. The majority of these immune-mediated reactions initially manifested during treatment; however, a minority occurred weeks to months after discontinuation ...

Amid the expanding noninvasive prenatal testing (NIPT) options, Dr. Liza Kunz joins Dr. Jennifer Caudle to discuss what differentiates genome-wide NIPT from other options, how it works, and its limitations and potential benefits.

Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents

Vallerie V McLaughlin, MD, FACC, FCCP; Richard Channick, MD; Teresa De Marco, MD, FACC, FHFSA; Harrison W Farber, MD, FCCP; Sean Gaine, MD, PhD; Nazzareno Galié, MD; Richard A Krasuski, MD; Ioana Preston, MD; Rogerio Souza, MD, PhD; J Gerry Coghlan, MD; Robert P. Frantz, MD; Anna Hemnes, MD; Nick H Kim, MD; Irene M Lang, MD; David Langleben, MD; Mengtao Li, MD; Olivier Sitbon MD, PhD; Victor Tapson, MD; Adaani Frost, MD

Funding was provided by Actelion to support the use of independent providers of Delphi methodology expertise and nominal group technique, survey creation, data analysis, medical communication, and meeting management. The authors were not paid an honorarium for their participation. Actelion played no role in the literature search and analysis, development of surveys used to gather consensus, or data analysis; and no Actelion employee was present at the meeting during which consensus statements were finalized. The manuscript was drafted, critically reviewed, and edited solely by the authors with support from an independent professional medical communications agency. Actelion Pharmaceuticals reviewed the final manuscript only to ensure accuracy of UPTRAVI® (selexipag) background ...

There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni.

©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Below please see Important Safety Information, including boxed WARNING, and Prescribing Information and Medication Guide at www.mavenclad.com.

Nearly one million individuals are afflicted with multiple sclerosis (MS) in the U.S. alone, with relapsing forms of MS being the most common.

Dr. Jennifer Caudle welcomes Dr. Timothy West, Dr. Donald Negroski, Mary Kay Fink and Dr. Elaine Edmonds to discuss treating patients with MAVENCLAD® (cladribine) tablets, the only treatment that can deliver proven efficacy in relapsing-remitting and active secondary progressive MS with a unique dosing schedule of up to 20 days of oral treatment over two years. The MS experts will walk through key clinical efficacy and safety data for MAVENCLAD, as well as provide their own perspectives on how the treatment fits into the current MS landscape and what patient types are best suited for treatment with MAVENCLAD.

MAVENCLAD has a boxed WARNING for malignancies and risk of teratogenicity. Do not take MAVENCLAD if you have a current malignancy, are pregnant or plan to become pregnant, have HIV or active chronic infection, have a hypersensitivity to cladribine or breastfeed during or for at least 10 days after the last dose. Follow recommended screening and monitoring prior ...

Under the CDC’s guidelines for providing quality contraceptive counseling, there are several important questions healthcare providers can ask their patients. That’s why Dr. Jan Shephard sits down with Erica, who provides a patient perspective on an effective contraceptive dialogue.

References

1. Gavin L et al. Providing quality family planning services: Recommendations of CDC and the U.S. Office of Population Affairs. MMWR Morb Mortal Wkly Rep. 2014;63:1‒54.
2. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: CCP and WHO, 2018.

US-XPL-00832 10/19

Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

Amgen's [BiTE]® technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE® platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Birnholz is joined by Dr. Ajai Chari.

USA-OCF-80679

The age-related decline in immunity is a dominant driver of shingles,1-3 an issue of special concern to older patients. Dr. Jeffrey Stoddard, US Medical Affairs Lead of Zoster Vaccines at GSK, discusses how SHINGRIX addresses this potentially serious health issue. You’ll hear about the vaccine’s high efficacy rates in patients 50 years and older,4 the results of pivotal clinical studies, CDC recommendations, and more.

References:

1. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13):1338-1343.
2. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30.
3. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494-500.
4. Prescribing Information for SHINGRIX.

Dr. Jan Shepherd and Dr. Jeff Levine discuss how engaging in a patient-centered dialogue with our patients can help increase their satisfaction and the likelihood that they will use their chosen method properly and consistently.

References

1. Gavin L et al. Providing quality family planning services: Recommendations of CDC and the U.S. Office of Population Affairs. MMWR Morb Mortal Wkly Rep. 2014;63:1‒54.
2. Gavin L et al. Update: Providing Quality Family Planning Services - Recommendations from CDC and the U.S. Office of Population Affairs, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:1383‒1385.
3. Wysocki S. The state of hormonal contraception today: enhancing clinician/patient communications. Am J Obstet Gynecol. 2011;205(4 suppl):S18–S20.
4. Finer LB et al. Declines in Unintended Pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374:843–852.
5. Sonfield A et al. Moving forward: Family planning in the era of health reform. Guttmacher Institute; March 2014. https://www.guttmacher.org/sites/default/files/report_pdf/family-planning-and-health-reform.pdf, Accessed January 17, 2019.

US-XPL-00789 08/19

Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

An average of 37.5 million menopausal women in the US between the ages of 45 and 64 experience symptoms such as hot flashes and joint pain, but there are other symptoms that we rarely talk about: symptoms like vaginal dryness and dyspareunia.

Featuring a patient and a panel of experts, this discussion reviews strategies that can be used to help patients feel comfortable in bringing up their struggles with menopause along with how we can help relieve women from their pain.

©2019 NP-INR-US-00214 09/19